Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 3, 2007 - Issue 4
Submit an article Journal homepage
94
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Targeted therapy for allergic asthma: predicting and evaluating response to omalizumab

Francesco Tarantini Pulmunologist, PhD student, DIMI – University of Genoa, Allergy & Respiratory Diseases, Padiglione Maragliano, Largo R. Benzi, 6, 16132 Genova, Italy. [email protected]
,
Fulvio Braido DIMI – University of Genoa, Allergy & Respiratory Diseases, Padiglione Maragliano, Largo R. Benzi, 6, 16132 Genova, Italy. [email protected]
,
Ilaria Baiardini Psychologist, PhD student, DIMI – University of Genoa, Allergy & Respiratory Diseases, Padiglione Maragliano, Largo R. Benzi, 6, 16132 Genova, Italy. [email protected]
,
Federica Fumagalli DIMI – University of Genoa, Allergy & Respiratory Diseases, Padiglione Maragliano, Largo R. Benzi, 6, 16132 Genova, Italy. [email protected]
,
Giovanni Passalacqua DIMI – University of Genoa, Allergy & Respiratory Diseases, Padiglione Maragliano, Largo R. Benzi, 6, 16132 Genova, Italy. [email protected]
&
Giorgio Walter Canonica DIMI – University of Genoa, Allergy & Respiratory Diseases, Padiglione Maragliano, Largo R. Benzi, 6, 16132 Genova, Italy. [email protected]
Pages 463-467 | Published online: 10 Jan 2014

References

  • Bousquet J, Rabe K, Humbert M et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir. Med.101(7), 1483–1492 (2007).
  • The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet351, 1225–1232 (1998).
  • Laoukili J, Perret E, Willems T et al. IL-13 alters mucociliary differentiation and ciliary beating of human respiratory epithelial cells. J. Clin. Invest.108, 1817–1824 (2001).
  • Erzurum SC. Inhibition of tumor necrosis factor α for refractory asthma. N. Engl. J. Med.354(7), 754–758 (2006).
  • Howarth PH, Babu KS, Arshad HS et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax60(12), 1012–1018 (2005).
  • Berry MA, Hargadon B, Shelley M et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N. Engl. J. Med.354(7), 697–708 (2006).
  • Cianci R, Cammarota G, Raducci F, Pandolfi F. The impact of biological agents interfering with receptor/ligand binding in the immune system. Eur. Rev. Med. Pharmacol. Sci.9(6), 305–314 (2005).
  • Soler M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J.18, 254–261 (2001).
  • Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy60, 309–316 (2005).
  • Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest125, 1378–1386 (2004).
  • Buhl R, Hanf G, Soler M et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur. Respir. J.20, 1088–1094 (2002).
  • Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. (2), CD003559 (2006).
  • Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. Br. Med. J.318(7183), 593–596 (1999).
  • Schwartz RS. Paul Ehrlich’s magic bullets. N. Engl. J. Med.350(11), 1079–1080 (2004).
  • Leung DY, Sampson HA, Yunginger JW et al. Avon Longitudinal Study of Parents and Children Study Team. Effect of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med.348(11), 986–993 (2003).
  • Leynadier F, Doudou O, Gaouar H et al. Effect of omalizumab in health care workers with occupational latex allergy. J. Allergy Clin. Immunol.113(2), 360–361 (2004).
  • Kuehr J, Brauburger J, Zielen S et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol.109(2), 274–280 (2002).
  • Casale TB, Busse WW, Kline JN et al. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol.117(1), 134–140 (2006).
  • Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J. Am. Acad. Dermatol.54(1), 68–72 (2006).

Website

  • Global Initiative for Asthma (GINA) www.ginasthma.com

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.